Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...

The bills, which have advanced in the Senate, would require schools to take certain preventative measures to protect student ...

Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...

GLP-1 (glucagon-like peptide) medications, such as Ozempic and Wegovy, have seen a surge in popularity over the past few ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...

Insulin resistance supplements supposedly help you lower your blood sugar and maintain a healthy weight. Experts explain how ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

The demand for glucagon-like peptide 1 (GLP-1) receptor agonists for overweight/obesity has created a clinical conundrum for ...

Gvoke VialDx is a concentrated liquid glucagon product. For diagnostic procedures, it works as a gastrointestinal motility inhibitor. The product is supplied as a single-dose vial containing 1mg of ...